Aurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation […]